DISCONTINUED: Stages of Development for Epicatechin

The drug development process can be thought of as a series of stages, and drugs must successfully pass through each stage to become available to patients. This treatment has been evaluated, and the program has been discontinued. Thus, it is not in the pipeline.

Link to Study

Safety and tolerability of (+)-epicatechin was demonstrated in healthy volunteers and individuals with neuromuscular disease (Becker Muscular Dystrophy)

2016-2017: Cardero and investigators at the Mayo Clinic ran a pilot study in 10 individuals with Friedreich ataxia. This was an open-label study for 24-weeks to evaluate the safety and effectiveness of synthetically produced (+) Epicatechin in treating patients who have FA.

There was no statistically significant change in FARS.